This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01054820
First received: January 20, 2010
Last updated: July 10, 2012
Last verified: July 2012
January 20, 2010
July 10, 2012
January 2010
March 2010   (Final data collection date for primary outcome measure)
Mean Change From Baseline to End of Treatment (EOT) in Response to Modified Brief Pain Inventory (mBPI) Question 5: Average Pain Over the Last 24 Hours [ Time Frame: Baseline, End of Treatment (last visit up to Day 15) ]
Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 5: Please rate your pain by marking the box beside the number that best describes your pain on the average (over the last 24 hours); rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).
Mean change from Baseline to the end of treatment (average of last 3 days of treatment) in Brief Pain Inventory (BPI) score of average pain (over the last 24 hours). [ Time Frame: Baseline to end of treatment (1-2 weeks) ]
Complete list of historical versions of study NCT01054820 on ClinicalTrials.gov Archive Site
  • Number of Participants With Change From Baseline (Bsl) to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 1: Pain Other Than Everyday Kind of Pain [ Time Frame: Baseline, End of Treatment (last visit up to Day 15) ]
    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 1: Have you had pain other than everyday kinds of pain?; response = Yes or No.
  • Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 3: Pain at Its Worst in the Last 24 Hours [ Time Frame: Baseline, End of Treatment (last visit up to Day 15) ]
    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 3: Rate your pain at its worst in the last 24 hours; rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).
  • Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 4: Pain at Its Least in the Last 24 Hours [ Time Frame: Baseline, End of Treatment (last visit up to Day 15) ]
    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 4: Rate your pain at its least in the last 24 hours; rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).
  • Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 6: Pain Right Now [ Time Frame: Baseline, End of Treatment (last visit up to Day 15) ]
    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 6: Rate your pain right now; rated on an 11 point Likert rating scale ranging from 0 (no pain) to 10 (pain as bad as you can imagine).
  • Mean Change From Baseline to EOT in Response to Modified Brief Pain Inventory (mBPI) Question 8: Percent Reduction in Pain From Baseline [ Time Frame: Baseline, End of Treatment (last visit up to Day 15) ]
    Participant-rated instrument to assess functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life) in past 24 hours. Question 8: Rate your percent reduction in pain from Baseline (0% = no relief to 100% = complete relief).
  • Number of Participants Per Global Pain Relief Scores at the End of Treatment as Assessed by the Participant [ Time Frame: End of Treatment (up to Day 15) ]
    Global pain relief as assessed by participant using a 5-point scale where 5 = complete relief, 4=a lot of improvement, 3=moderate improvement, 2=slight improvement, and 1=no change.
  • Number of Participants Per Global Pain Relief Scores at the End of Treatment as Assessed by the Investigator [ Time Frame: End of Treatment (up to Day 15) ]
    Participants' global pain relief as assessed by investigator using a 5-point scale where 5 = complete relief, 4=a lot of improvement, 3=moderate improvement, 2=slight improvement, and 1=no change.
  • Mean Change From Baseline to EOT in Beck Depression Inventory® Il [ Time Frame: Baseline, End of Treatment (last visit up to Day 15) ]
    The Beck Depression Inventory® II consisted of 21 items, each with 4 categorical responses ranging from 0 (I do not feel sad) to 3 (I am so sad or unhappy that I can't stand it) with maximum possible score of 63; increase in the number reflected an increase in severity. Total Beck Depression Inventory® II scores classified as follows: 1 to 10=normal ups and downs; 11 to 16=mild mood disturbance; 17 to 20=borderline clinical depression; 21 to 30=moderate depression; 31 to 40=severe depression; and >40=extreme depression.
  • Number of Participants Per Patch Satisfaction Response at the End of Treatment as Assessed by Participant [ Time Frame: End of Treatment (last visit up to Day 15) ]
    Participant satisfaction with the FLECTOR® Patch rated on a 5-point scale scored as 5=Very Satisfied, 4=Satisfied, 3=No Preference, 2=Dissatisfied, and 1=Very Dissatisfied.
  • Number of Participants Per Patch Satisfaction Response at the End of Treatment as Assessed by the Investigator [ Time Frame: End of Treatment (last visit up to Day 15) ]
    Investigator's assessment of participants' satisfaction with the FLECTOR® Patch rated on a 5-point scale scored as 5=Very Satisfied, 4=Satisfied, 3=No Preference, 2=Dissatisfied, and 1=Very Dissatisfied.
  • Mean change from Baseline to the end of treatment in BPI score of worst pain. [ Time Frame: Baseline to end of treatment (1-2 weeks) ]
  • Mean change from Baseline to the end of treatment in BPI score of least pain. [ Time Frame: Baseline to end of treatment (1-2 weeks) ]
  • Mean change from Baseline to the end of treatment in BPI score of current pain. [ Time Frame: Baseline to end of treatment (1-2 weeks) ]
  • Subject global pain relief scores at the end of treatment. [ Time Frame: End of treatment (1-2 weeks) ]
  • Investigator global pain relief scores at the end of treatment. [ Time Frame: End of treatment (1-2 weeks) ]
  • Mean change from Baseline to the end of treatment in total score of Beck Depression Inventory® II. [ Time Frame: Baseline to end of treatment (1-2 weeks) ]
  • Subject patch satisfaction scores at the end of treatment. [ Time Frame: End of treatment (1-2 weeks) ]
  • Investigator patch satisfaction scores at the end of treatment. [ Time Frame: End of treatment (1-2 weeks) ]
Not Provided
Not Provided
 
Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain
Multicenter, Open-Label Study to Assess the Effectiveness and Safety of FLECTOR Patch for Treatment of Acute Back Strain
Although approved for minor strains, sprains and contusions, FLECTOR Patch has not been studied extensively in the setting of acute back strain. This study is being conducted as an initial step in demonstrating the benefit of FLECTOR Patch specifically for back strain. In particular, this study is expected to provide information about the amount of improvement in back strain among subjects using the FLECTOR Patch, which may then be used to inform subsequent studies.
Not Provided
Interventional
Phase 4
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Acute Back Strain
Drug: FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%
One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
Experimental: FLECTORA Patch (diclofenac epolamine topical patch) 1.3%
One patch applied every 12 hours
Intervention: Drug: FLECTOR® Patch (diclofenac epolamine topical patch) 1.3%
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
123
March 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Participants in the study must:

  1. have acute, non-radicular back strain with onset up to 10 days before the first visit
  2. have intact, non-damaged skin at the proposed patch application site
  3. be untreated or unresponsive to conservative pain treatment regimens and/or opioids
  4. have a minimum pain intensity score of four (4) or more on a scale of 1-10 (a rating of zero (0) being "no pain" and a rating of ten (10) being "pain as bad as you can imagine")
  5. have a normal neurologic examination

Exclusion Criteria:

Participants may not be in the study if they:

  1. have had surgery or other chronic pain condition within 3 months before first treatment
  2. have back pain radiating below the knee at time of enrollment
  3. have neuropathic pain or have been treated with gabapentin or pregabalin for neuropathy
  4. are being treated for or are known to currently have kidney or liver disease
  5. have certain other diseases or are using certain types of other drugs.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
United States
 
NCT01054820
K353-09-4001
B4811001
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP